Featured Stories

Over the years, Medicilon has been actively empowering the upgrading of life sciences and building a platform to promote the integrated development of the biomedical industry. In 2019, starting from the 15th anniversary, a national tour of seminars was launched, and seven pre-clinical research related seminars were successively held. The Medicilon research team shared theRead more

SARS-CoV-2 is an enveloped single-stranded RNA virus. The viral RNA produces two polyproteins: pp1a and pp1ab through ribosome frameshift. The polyprotein is processed by the papain-like protease (PL pro), which cuts 3 sites to release the non-structural protein nsp1-3 and a 3C-like protease, also known as the main protease (M pro). Cut at 11 sitesRead more

Shanghai, China, October 15, 2020-Shanghai Medicilon and Phenomenex reached a strategic agreement to jointly build a chemistry laboratory for chiral interchange and further enhance the scientific research of Medicilon’s drug discovery platform, helping more customers with new drug research. Medicilon’s drug discovery platform serves the early stages of new drug research and development projects, andRead more

Oct 16th, Hainan, China—The 15th Award of competitive and trustworthy listed companies in China was held in Sanya, Hainan. The theme of the forum was “the prospect of the capital market driven by the ‘double cycle’”. The attendees included experts and KOL from different industries and entrepreneurs from hundreds of successful listed companies. They gatheredRead more

With the development of bispecific antibody technology, bispecific antibody now presents a good development prospect. When major companies are deploying bi-antibody product research and development, they also need to pay attention to the detection and analysis of bi-antibody. Points to note and consider. Dr. Zhang Dengji, Director of Pharmaceutical Analysis Department of Medicilon Biotechnology, broughtRead more